Initiator Pharma A/S rights issue oversubscribed
Pharma People on the Move: Fall 2022 Roundup – PharmaLive
Initiator Pharma's issue of units oversubscribed
Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition - ScienceDirect
Recent advancements in applications of ionic liquids in synthetic construction of heterocyclic scaffolds: A spotlight - ScienceDirect
PCI Pharma Services | Contract Pharma
Detailed Understanding of Solvent Effects for the Cationic Ring-Opening Polymerization of 2-Ethyl-2-oxazoline | Macromolecules
Market Notice 156/21 – Information regarding the rights issue from Initiator Pharma A/S
Biomedical researchers have a new treatment of erectile dysfunction on the way
Reactions | Free Full-Text | Recent Progresses in the Preparation of Chlorinated Molecules: Electrocatalysis and Photoredox Catalysis in the Spotlight
Adare Pharma Solutions | Contract Pharma
INITIATOR PHARMA: YEAR END REPORT 2019
Initiator Pharma
Invitation to subscribe for shares in
The Board of Directors of Initiator Pharma A/S decides on execution of previously communicated preferential rights issue
Preformed mediators of defense—Gatekeepers enter the spotlight - Ricklin - 2016 - Immunological Reviews - Wiley Online Library
Initiator Pharma A/S publishes information memorandum in connection with the change of listing to Nasdaq First North Growth Mark
Perimeter Protection: Top 10 X-ray Images
Initiator Pharma - Phase 2a study with IP2018 update
DLA Piper assists Initiator Pharma A/S with list change from Spotlight Stock Market to Nasdaq First North Growth Market Sweden | DLA Piper
